Quidel to Host Virtual Investor Day on November 12, 2020
November 03 2020 - 4:10PM
Business Wire
Quidel Corporation (NASDAQ:QDEL), provider of rapid
diagnostic testing solutions, cellular-based virology assays and
molecular diagnostic systems, announced today that it will host its
Quidel Investor Day 2020 event virtually on Thursday, November 12,
2020.
Quidel’s management presentation will begin at 8:00 a.m. Pacific
Time, to be immediately followed by a question and answer session.
During the presentation, the Company will discuss business and
financial developments and trends. The Company's statements may
contain or constitute material information that has not been
previously disclosed.
To access and register for the Quidel Investor Day 2020 event,
please go to Quidel’s Investor Relations page
(https://ir.quidel.com), or click on the following presentation
link: https://primetime.bluejeans.com/a2m/register/wedkvpue
A live webcast and audio archive of the presentation will be
available via the Investor Relations section of the company’s Web
site at www.quidel.com. Participants should allow approximately
five to ten minutes prior to the presentation's start time to visit
the site and download any streaming media software needed to listen
to the Internet webcast. A replay of the webcast will also be
available on the company’s Web site for 90 days.
About Quidel Corporation
Quidel Corporation serves to enhance the health and well-being
of people around the globe through the development of diagnostic
solutions that can lead to improved patient outcomes and provide
economic benefits to the healthcare system. Marketed under the
Sofia®, QuickVue®, D3® Direct Detection, Thyretain®, Triage® and
InflammaDry® leading brand names, as well as under the new Solana®,
AmpliVue® and Lyra® molecular diagnostic brands, Quidel’s products
aid in the detection and diagnosis of many critical diseases and
conditions, including, among others, COVID-19, influenza,
respiratory syncytial virus, Strep A, lyme, herpes, pregnancy,
thyroid disease and fecal occult blood. Quidel's Triage® system of
tests comprises a comprehensive test menu that provides rapid,
cost-effective treatment decisions at the point-of-care (POC),
offering a diverse immunoassay menu in a variety of tests to
provide diagnostic answers for quantitative BNP, CK-MB, d-dimer,
myoglobin, troponin I and qualitative TOX Drug Screen. Quidel’s
research and development engine is also developing a continuum of
diagnostic solutions from advanced immunoassay to molecular
diagnostic tests to further improve the quality of healthcare in
physicians’ offices and hospital and reference laboratories. For
more information about Quidel’s comprehensive product portfolio and
to explore exciting employment opportunities, visit quidel.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201103005704/en/
Quidel Contact: Quidel Corporation Randy Steward Chief Financial
Officer (858) 552-7931
Media and Investors Contact: Quidel Corporation Ruben Argueta
(858) 646-8023 rargueta@quidel.com
QuidelOrtho (NASDAQ:QDEL)
Historical Stock Chart
From Jun 2024 to Jul 2024
QuidelOrtho (NASDAQ:QDEL)
Historical Stock Chart
From Jul 2023 to Jul 2024